Accès membres

Bienvenue sur le site du Groupe d’étude des Tumeurs Endocrines

Le groupe d'étude des tumeurs endocrines est une société savante créée en 2002 réunissant les différentes spécialités impliquées dans la prise en charge des tumeurs neuro-endocrines (TNE) : anatomopathologistes, biologistes, chirurgiens, endocrinologues, gastroentérologues, généticiens, médecins nucléaires, oncologues et radiologues.

BEVANEC

Folfiri +/- Bevacizumab après échec platine-étoposide - financement PHRC 2014 - ouverture 1er semestre 2017

Type d'étude Promoteur Etat actuel de l'étude
Phase II-R HCL/Prodige En cours d'ouverture

 

Assessment of the efficacy of bevacizumab in combination with Folfiri as second-line treatment after the failure of the cisplatin (or carboplatin)-etoposide combination in patients suffering from an advanced inoperable poorly differentiated neuroendocrine carcinoma of an unknown or gastroentero-pancreatic primary cancer. A phase 2 non-comparative randomized study"

Code de l’étude

Prodige 41 – BEVANEC study

Sponsor

Hospices Civils de Lyon / Prodige

Coordinator

Thomas WALTER,  Mail Walter

Objectives

•    Main objective: to show that, after the failure of a first-line chemotherapy using platinum-etoposide, the combination Folfiri-bevacizumab allows significant prolongation of overall survival in adult patients with GEP-NEC.
•    Secondary objectives
   - Objective response rate (complete response + partial response),
   - Response duration
   - Disease control rate (objective response + stable disease),
   - Progression-free survival,
   - Tolerance,
   - Biochemical response (LDH, NSE, chromogranin A).

Methodology / Design of the research

 A national, multicenter, open, randomized phase II non-comparative study assessing the tolerance and efficacy of the combination Folfiri-bevacizumab versus a Folfiri chemotherapy after the failure of platinum-etoposide in patients suffering from progressive NEC of unknown or GEP primary cancer.

Inclusion criteria

•    Man or woman aged > 18 years old,
•    Poorly differentiated neuroendocrine carcinoma (NEC) from a GEP primary or an unknown primary cancer, locally advanced and/or metastatic (according to the WHO 2010),
•    Centralized review of the diagnostic by a consulting pathologist specializing in NET (TENPATH network),
•    Recommendation of a second-line chemotherapy after progression, documented using the RECIST criteria v.1.1, and after a first-line chemotherapy treatment by cisplatin (or carboplatin) + etoposide or in the event of progression in the 6 months following the discontinuation of this first-line treatment,
•    Patients presenting at least one measurable target lesion according to the RECIST criteria v.1.1, in an area not previously irradiated,
•    General condition < 2 (WHO),
•    Patient who signed the informed consent form.

Non inclusion criteria

Relating to the tumor, the patient, and previous treatment:
•    Well differentiated gastroentero-pancreatic (GEP) neuroendocrine tumor (NET) (G1 and G2 according to the WHO 2010),
•    Mixed tumor,    
•    First-line chemotherapy other than cisplatin (or carboplatin) and etoposide,
•    All malignant disease in the three years before randomization, with the exception of basal cell carcinoma or in situ cervical cancer treated for curative purposes,
•    A pregnant or breastfeeding woman,
•    Lack of efficient contraception (for men or women of reproductive age),
•    All medical, geographical, social, and psychological conditions or a legal situation that will not allow the patient to finish the study or sign an informed consent form,

Relating to the chemotherapy (Folfiri):
•    Any of the following uncontrolled progressive diseases in the 6 months before randomization: liver failure, renal insufficiency, respiratory distress, congestive heart failure (NYHA III-IV), unstable angina, myocardial infarction, significant arrhythmia,
•    Known deficiency in dihydropyrimidine dehydrogenase,
•    Known Gilbert's syndrome,
•    Total bilirubin level >1.5x the upper limit of normal (ULN); AST and/or ALT >5x ULN; TP <50%;
•    Neutrophils <1.5x109/l, platelets <100x109/l, hemoglobin <10 g/dl,
•    Chronic uncontrolled diarrhea, unresolved intestinal occlusion or subocclusion,
•    History of anaphylactic reaction or known intolerance to atropine (sulfate) or to loperamide or to antiemetics administered in association with Folfiri,
•    All treatment with concomitant anticonvulsive agents, CYP3A4 inducers (phenytoin, phenobarbital, carbamazepine), discontinued for at least 7 days,

Relating to bevacizumab:
•    Uncontrolled brain metastases (by local treatment),
•    All uncontrolled progressive disease within 1 month prior to randomization: grade 3-4 gastrointestinal bleeding (peptic ulcer, erosive esophagitis or gastritis), infectious disease or intestinal inflammation, diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event,
•    Uncontrolled high blood pressure defined as a systolic blood pressure >140 mmHg or diastolic pressure >90 mmHg,
•    Patients receiving anticoagulant treatment with an unstable dose of a vitamin K antagonist treatment, and/or having an abnormal INR (>3) in the four weeks before the randomization,
•    Verified proteinuria above or equal to 1g/24 hours measured from 24 hours of urine if the urinary protein dipstick control is above or equal to 2+,  
•    Creatinine clearance (MDRD) <50 ml/min.
•    Hypersensitivity to the active substance or to any of the excipients.
•    Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies.

Number of subjects

124 patients